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Abstract
High-grade gliomas (HGGs) of childhood represent approximately 7% of pediatric brain tumors. They are highly
invasive tumors and respond poorly to conventional treatments in contrast to pilocytic astrocytomas, which usually
are well demarcated and frequently can be cured by surgery. The molecular events for this clinical relevant finding
are only partially understood. In the current study, to identify aberrantly methylated genes that may be involved
in the tumorigenesis of pediatric HGGs, we performed a microarray-based differential methylation hybridization
approach and found frequent hypermethylation of the LHX9 (human Lim-homebox 9) gene encoding a transcrip-
tion factor involved in brain development. Bisulfite genomic sequencing and combined bisulfite restriction analysis
showed that HGGs were frequently methylated at two CpG-rich LHX9 regions in comparison to benign, nondiffuse
pilocytic astrocytomas and normal brain tissues. The LHX9 hypermethylation was associated with reduced mes-
senger RNA expression in pediatric HGG samples and corresponding cell lines. This epigenetic modification was
reversible by pharmacological inhibition (5-aza-2′-deoxycytidine), and reexpression of LHX9 transcript was induced
in pediatric glioma cell lines. Exogenous expression of LHX9 in glioma cell lines did not directly affect cell proliferation
and apoptosis but specifically inhibited glioma cell migration and invasion in vitro, suggesting a possible implication
of LHX9 in the migratory phenotype of HGGs. Our results demonstrate that the LHX9 gene is frequently silenced
in pediatric malignant astrocytomas by hypermethylation and that this epigenetic alteration is involved in glioma cell
migration and invasiveness.
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Introduction
High-grade astrocytomas (World Health Organization [WHO] grades 3
and 4) are considered to derive from astrocytic precursor cells. Malignant
anaplastic astrocytoma and glioblastoma of childhood are infrequent
compared with their adult counterparts and comprise approximately
7% of pediatric brain tumors [1]. Although the survival rates have in-
creased during the recent years, especially because of better surgical
techniques and postoperative treatment, the prognosis is still poor com-
pared with nondiffuse pilocytic astrocytomas (PAs; WHO grade 1),
which usually are demarcated and frequently can be cured by surgery.
Carcinogenesis, in general, is a multiple-step process that may
involve both genetic and epigenetic changes. Alterations of DNA
methylation seem to be early events and occur more frequently than
individual genetic changes [2]. Epigenetic changes especially DNA
methylation of the promoter CpG islands (CGIs) and consequent
gene silencing are important processes for both initiation and pro-
gression of human cancers. Aberrant methylation of CGI-associated
promoter regions of genes is a frequent epigenetic event in tumor cells
accompanied by alterations in histone modification and chromatin
conformation rendering the CGI and its associative promoter tran-
scriptionally inert [3]. Such epigenetic modifications have been re-
ported to be widespread and likely contribute to gliomagenesis [4,5].
For example, in human gliomas, epigenetic alterations are implicated
in the silencing of genes involved in the regulation of cell cycle (RB,
p16INK4A, p73), DNA repair (MGMT), apoptosis (DAP kinase 1),
angiogenesis (THBS1), and invasion (TIMP3) [6].
Differential methylation hybridization (DMH) is one of the global
techniques developed to analyze alterations of DNA methylation
in human cancer using CGI microarrays [7]. In the current study,
we applied DMH to identify aberrantly methylated genes that may
be involved in tumorigenesis of pediatric high-grade gliomas (HGGs)
and found frequent hypermethylation of LHX9, LIM-homeodomain
(LIM-hd) 9 transcription factor, which belongs to a family of devel-
opmental regulators. It is expressed in embryonic mouse brain, with
the highest level of expression in the diencephalon, telencephalic
vesicles, and dorsal mesencephalon [8]. The expression pattern and
structural characteristics of LHX9 suggest that it encodes a transcrip-
tion factor that might be involved in the control of cell differentia-
tion of several neural cell types [9]. The DNA methylation status of
human LHX9 has not been previously analyzed. In this study, we
describe for the first time that LHX9 is frequently inactivated in
malignant astrocytomas and glioma cell lines by the hypermethylation
of the CGI-associated region within the gene compared with benign
pediatric PAs and normal brain tissue samples. The hypermethyla-
tion is associated with a reduced expression of LHX9 and can be re-
stored after treatment with a demethylating agent. Functional analyses
suggest that LHX9 silencing is specifically involved in the migratory
and invasive potential of pediatric malignant gliomas.
Materials and Methods
Glioma Samples and Cell Lines
Glioma samples were obtained from 39 pediatric (aged ≤18 years)
patients and were classified according to theWHO classification criteria
using histological and immunological methods [10]. The tumor series
included 14 PAs, WHO grade 1, 14 anaplastic astrocytomas WHO
grade 3, and 11 glioblastoma multiforme (GBM) WHO grade 4.
The pediatric patients have been enrolled in the multicenter treatment
study for pediatric malignant brain tumors of the German Society of
Pediatric Oncology and Hematology (HIT-GBM) [11]. Biopsies of the
white matter of brain of three pediatric patients with epilepsy or congeni-
tal malformations were included as nonpathological controls. The study
was approved by the ethics committee of the University of BonnMedical
Center. To exclude contaminations by normal or necrotic tissues, frozen
tissue materials were selected for DNA and RNA extractions after careful
examination of corresponding hematoxylin-eosin–stained sections. All
samples selected contained at least 80% of vital tumor.
The glioma cell line CHLA-200 was derived from an 8-year-old pa-
tient with anaplastic astrocytoma (Xu and Reynolds, unpublished obser-
vations) and was kindly provided by Dr. Reynolds from USC-CHLA
Institute for Pediatric Clinical Research, Los Angeles. CHLA-200 cells
were cultured in Iscove’s modified Dulbecco’s medium (Invitrogen,
Karlsruhe, Germany) supplemented with 20% fetal calf serum (FCS;
Invitrogen), 2 mM L-glutamine and human insulin-transferrin–selenous
acid solution (Invitrogen). Cell lines KNS-42 derived from a 16-year-old
patient with glioblastoma and KG-1-C derived from a 13-year-old pa-
tient with mixed glioma were purchased from the Japanese Collection of
Research Bioresources and Health Science Research Resources Bank,
whereas the SF188 cell line derived from an 8-year-old patient with
glioblastoma was obtained from the UCSF/Neurosurgery Tissue Bank.
Cells were cultured in Dulbecco’s modified Eagle medium (Invitrogen)
supplemented with 10% FCS and 2 mM L-glutamine. All cell lines were
maintained at 37°C in a 5% CO2 atmosphere.
DNA samples derived from normal testis tissues were kindly provided
by Dr. K. Biermann, Department of Pathology, University of Bonn.
DNA and RNA Extraction
Genomic DNA was obtained from frozen tissues by standard pro-
teinase K digestion and phenol-chloroform extraction and from glioma
cell lines using QIAamp DNA Mini tissue Kit (Qiagen, Duesseldorf,
Germany). Total RNA from frozen tissue samples and cell lines was
isolated using TRIZOL reagent (Invitrogen) according to the manu-
facturer’s instructions. To remove any contaminating genomic DNA,
the total RNAwas digested with 10 U of RNase-free DNase (Promega,
Mannheim, Germany) and 40 U of RNasin (Promega) in a volume
of 30 μl before reverse transcription. The RNA was reverse-transcribed
using the Superscript II Preamplification System (Invitrogen) with
random hexamers as primers in a final volume of 20 μl.
Differential Methylation Hybridization Analysis and
CGI Identification
The DMH procedure was performed as described [12]. CpG-rich
DNA fragments were isolated from the human CGI library and screened
for the presence of BstUI and HpaII (New England Biolabs GmbH,
Frankfurt, Germany) restriction sites. Sixteen thousand suitable frag-
ments were polymerase chain reaction (PCR)–amplified using plasmid
primer and spotted onto UltraGAPS microarrays (Corning, Acton,
MA). For amplicon generation, 2 μg of genomic DNA derived from
nine pediatric malignant astrocytic tumors and a pool of control
DNA obtained from the white matter of three pediatric brain tissue
samples were digested withMseI (New England Biolabs). After ligation
of linkers H12/H24 (New England Biolabs), fragments were digested
with methylation-sensitive restriction endonucleases BstUI and HpaII
and amplified for 20 cycles with H24 as a primer. Polymerase chain
reaction fragments were labeled with the Alexa Fluor 555 (normal
brain) and Alexa Fluor 647 (tumor) dyes using the BioPrime Plus Array
CGH Indirect Genomic Labeling Kit (Invitrogen). Equal amounts of
the labeled and purified amplicons and 10 μg of human Cot-1 DNA
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(Invitrogen) were cohybridized onDMHmicroarrays.Hybridization and
analysis were carried out as described [7]. Data from single-copy se-
quences were normalized, and loci with an Alexa Fluor 647/Alexa Fluor
555 ratio greater than 2.5 were empirically scored as hypermethylated.
The DMH strategy provided information on a CGI-associated re-
gion that comprised 3 intron/4 exon within LHX9 transcript variant
2 (GenBank accession number NM_001014434). CpG island at the
5′-putative promoter region of LHX9 was identified using a CGI
searcher program (http://www.ebi.ac.uk/emboss/cpgplot/) and predicted
to possess promoter or enhancer activity using Promoter 2.0 prediction
program [13].
Bisulfite Modification and Genomic Sequencing
Bisulfite modification of 500 ng of genomic DNA obtained from tis-
sue samples and cell lines was performed using the EpiTect Bisulfite Kit
(Qiagen) according to the manufacturer’s instructions. The sequences of
the primers used for amplification of the 5′-LHX9 putative promoter
region are listed in Table 1. Polymerase chain reaction was done with
2 μl of bisulfite-treated DNA in a final volume of 30 μl containing
PCR buffer, 0.5 μM of each primer, 200 μM of each dNTP, 2 mM
MgCl2, and 2.5 U Platinum Taq DNA polymerase (Invitrogen). The
339-bp product containing 22 CpG methylation sites was separated
on a 2.5% agarose gel, purified using a QIAquick Gel Extraction Kit
(Qiagen), and cloned with the pGEM-T Vector System Kit (Promega).
Colony PCR was performed on 8 to 10 white colonies to validate the
insert. The obtained PCR products were sequenced by GATC-Biotech
AG (Konstanz, Germany) and analyzed by BiQ Analyzer Software [14].
Combined Bisulfite Restriction Analysis
The 5′ CGI-associated putative promoter region (LHX9 region 1)
and CpG-rich fragment within the LHX9 gene (LHX9 region 2; Fig-
ure 1A) were quantitatively analyzed by combined bisulfite restriction
analysis (COBRA) in 39 pediatric gliomas including those tissue
samples which have been examined by DMH and four glioma cell
lines. Nonpathological brain tissue samples were used as controls.
The bisulfite-converted DNA were used for a single amplification of
the LHX9 region 1. A nested PCR was set up to amplify the LHX9
region 2. Polymerase chain reaction products generated with LHX9
primers (sequences are listed in Table 1A) specific for bisulfite-converted
DNA as well as SssI-modified genomic DNA used as a fully methylated
control were digested with the restriction endonuclease BstUI (5′-
CGCG-3′) for LHX9 region 1 or a combination of two endonucleases
BstUI and TaqαI (5′-TCGA-3′; New England Biolabs) for the second
LHX9 fragment, and subsequently separated on a 4% agarose gel as
Table 1. Sequences of the (A) Two CpG-rich Regions of LHX9 Analyzed and (B) Primers Used for Amplification Reactions.
(A) Sequences of the CpG-rich regions of LHX9 gene showing the positions of CpG sites (cg) in gray and the primers (bold italic) used for amplification after bisulfite treatment of genomic DNA. The
BstUI (5′-CGCG-3′) and TaqαI (5′-TCGA-3′) restriction sites are boxed. (B) Sequences of the primers (bis-) used for amplification of bisulfite-modified genomic DNA and the primers used for the cRT-
PCR, which were always chosen to span at least 1 intron. The cRT-PCR was described in the Materials and Methods section using T7-forward primer (italic) and deletion reverse primer. Arrow in the
sequence of the deletion reverse primer (DEL) indicates the deletion.
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described previously [15]. The LHX9 region 1 amplicon contains two
BstUI restriction sites, whereas the overlapping LHX9 region 2 prod-
ucts have one BstUI and one TaqαI restriction sites (Table 1A). If
LHX9 region 1 is unmethylated, the 339-bp PCR product remains
intact, whereas if it is methylated, this band is digested to 201-, 107-,
and 31-bp products. If LHX9 region 2 is unmethylated, both 169-
and 266-bp amplicons remain intact, whereas if it is methylated, the
169-bp band is digested with BstUI to 65- and 104-bp products or with
TaqαI to 70- and 99-bp products and the 266-bp band is digested with
BstUI to 71- and 195-bp products or withTaqαI to 81- and 185-bp prod-
ucts. The degree of DNA methylation of each sample was determined
as a ratio of signal intensity of the digested bands to that of all bands.
Treatment of Glioma Cells with Demethylating Agent
Glioma cell lines CHLA-200, SF188, and KNS-42 were grown in the
presence or absence of the demethylating agent 5-aza-2′-deoxycytidine
(5 μM 5-aza CdR; DNA methyltransferase inhibitor; Sigma-Aldrich,
Hannover, Germany) for 4 days. The medium was replaced daily.
Figure 1. Methylation profile of the two CpG-rich fragments of LHX9 gene in pediatric HGGs, PAs, and glioma cell lines. (A) Schematic
structure of the LHX9 gene including its chromosomal mapping, mRNA, and CGI content. Arrows indicate the positions of the two CpG-
rich regions analyzed by bisulfite sequencing or COBRA approaches. (B) Lollipop-style representation of the methylation status of 22 CpG
residues within the LHX9 CGI-associated putative promoter region 1 of one pediatric HGG (D2214-GBM) and one normal brain tissue sam-
ple. Filled (black) circles define methylated CpG site, open (white) circles display unmethylated CpG, and vertical lines without a circle cor-
respond to a single nucleotide polymorphism affecting one of the contained CpG sites. BstUI restriction sites (bold lines) are also indicated.
Methylation level of the LHX9 region 1 was also estimated by COBRA. The PCR products from bisulfite converted DNA samples were
digested with restriction endonuclease BstUI (see Materials and Methods). Picture of agarose gel electrophoresis represents the methyla-
tion profile of five HGGs, one normal brain control sample, and two cell lines. Scatter plot summarizes themethylation level of LHX9 region 1
in 25 HGG and 4 glioma cell lines. Seven cases (28%) were methylated and quantified to an average of 20% methylated alleles comparing
with the three nonpathological tissue sampleswhich were unmethylated. Two (50%) of the cell lines were hypermethylated. (C) Methylation
levels of the CpG-rich LHX9 region 2 were estimated by COBRA using a combination of two restriction endonucleases BstUI and TaqαI (see
Materials and Methods). The methylation status of five HGGs and two glioma cell lines is shown. Scatter plot summarizes the methylation
profile of LHX9 region 2. Of 25 HGGs, 22 (88%) were aberrantly methylated and quantified to an average of 51%methylated alleles; 4 (29%)
of 14 PAs showed a low level of methylation and quantified to an average of 10% methylated alleles compared with the unmethylated
normal brain control samples. The four cell lines were hypermethylated. The degree of methylation of each sample was determined as
a ratio of the signal intensity of the digested bands to that of all bands. SssI-treated genomic DNA was used as a fully methylated control.
The COBRA approach also showedmethylation level of the LHX9 region 2 in SF188 cells before and after treatment with the demethylating
agent 5-aza CdR (SF188 + 5aza).
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Total RNA was isolated from 1 × 106 cells using TRIZOL reagent
(Invitrogen), and the LHX9 messenger RNA (mRNA) expression levels
were analyzed by competitive reverse transcription–PCR (cRT-PCR).
The PCDH-γ-A11 gene (protocadherin-gamma subfamily A11), which
is known to be silenced by methylation in astrocytoma cells [16], was
used to verify the effect of 5-aza CdR treatment in our experiments.
Competitive RT-PCR Analysis
Total RNA was reverse-transcribed using the Superscript II Pre-
amplification System (Invitrogen). Polymerase chain reaction was set
up with LHX9 and β-actin specific primers (Table 1B) resulting in
amplicons of 240 bp for LHX9 and 384 bp for β-actin. RNA com-
petitor molecules with internal deletions for LHX9 and for the house-
keeping gene β-actin were generated by in vitro mutagenesis and
in vitro transcription as described [17]. The sizes of the mutated com-
petitor PCR products were 220 bp for LHX9 and 334 bp for β-actin.
For cRT-PCR, predetermined amounts of homologous exogenous com-
petitor RNA (from 0.8 to 150 pg) and 250 ng of total RNAwere reverse-
transcribed. Polymerase chain reaction amplifications were carried
out with fluorescently (6-carboxyfluorescein (FAM))–labeled reverse
primers (Invitrogen). Optimal titration was defined as the point of equal
signal intensity of exogenous competitor and target transcript. The re-
sulting products were separated on a 4.5% denaturing acrylamide gel
and analyzed on a semiautomated DNA Sequencer ABI 377 (Applied
Biosystems, Darmstadt, Germany) using the Gene Scan Analysis Soft-
ware version 3.1.
Transfection Experiments
To exogenously express LHX9, SF188 and KNS-42 glioma cell lines
were cultured overnight on 60-mm tissue culture dishes (1 × 104) and
cotransfected with a pCMV6-XL4/LHX9 plasmid containing full-
length LHX9 cDNA (2 μg) and pRS vector containing the puromycin-
resistant gene (Origene, AMS Biotechnology, United Kingdom) using
Lipofectamine 2000 (Invitrogen) as recommended by the protocol of
the manufacturer. Cells transfected with empty plasmid vector (mock)
were used as controls. After 24 hours of transfection, the cells were treated
with 5 μg/ml puromycin (Sigma) for the selection of stable transfectants.
After 14 days of selection, the stable cell clones (SF188-LHX9 and KNS-
42-LHX9) were tested for mRNA and protein expression of LHX9 by
RT-PCR and Western blot analyses and were used for further experi-
ments. Green fluorescent protein–positive cells transfected with GFP-
expressing vector were used as a control for efficiency of the transfections.
Western Blot Analysis
Nuclear extracts of puromycin-resistant SF188-LHX9, KNS-42-
LHX9 and mock cells (at 8.8 × 106) were prepared with a nuclear ex-
traction kit (Active Motif SA, Rixensart, Belgium) according to the
manufacturer’s instructions, and protein concentration of the soluble
lysates was determined using the Bradford assay. Ten micrograms of
the nuclear extracts was separated by a 4% to 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (NuPAGE; Invitrogen)
under reducing conditions and were transferred to nitrocellulose mem-
branes. The membranes were blocked with 5% bovine serum albumin
in TBS–0.1% Tween 20 for 2 hours at room temperature and probed
with primary antibodies at 4°C overnight. After washing, the mem-
branes were incubated with horseradish peroxidase–conjugated second-
ary antibodies at room temperature for 1 hour. The primary antibodies
included rabbit polyclonal antibody against Lhx9 (51 kDa; Abcam,
Cambridge, United Kingdom) and anti–mouse monoclonal β-actin
antibody (42 kDa; Sigma). The bound antibodies were visualized using
an ECL system (Amersham Biosciences, United Kingdom).
Colony Focus Assay
A total of 1 × 104 cells were transfected three times in triplicate on
60-mm tissue culture dishes. After 24 hours of transfection, LHX9-
transfected and mock-transfected cells were cultured in a selection me-
dium containing 5 μg/ml puromycin for 14 days. Stable cell clones
were stained with 0.1% crystal violet in 20% methanol for 10 minutes
in the dark, and colonies with 50 cells or more were counted.
Cell Growth and Proliferation Assays
For the growth curve assay, a total of 1 × 104 transfected and
puromycin-selected cells were plated three times in triplicate on 12-well
culture plates for 24, 48, and 72 hours. Cells were harvested with
0.25% trypsin and 1 mM EDTA in medium (Invitrogen), and the
number of cells was counted with a hemacytometer under microscopic
observation. Results were expressed as a mean number of cells.
Glioma cell proliferation was analyzed by a 3-(4,5-dimethylthiazole-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Cell Proliferation Kit I;
Roche, Mannheim, Germany) according to the manufacturer’s instruc-
tions. Puromycin-resistant LHX9-transfected and mock-transfected
cells (5 × 103) were cultured three times in triplicate on 96-well culture
plates for 24, 48, and 72 hours. The cell proliferation was determined
by measuring the converted formazan at 595 nm using a microplate
reader (BioAnalyzer; BioTek, Bad Friedrichshall, Germany).
Transwell Cell Migration and Scratch Assays In Vitro
The migratory potential of transfected cells after puromycin selec-
tion for 14 days was estimated by a transwell migration assay as pre-
viously described [18] using transwell insert containing a 8-μm pore
size polycarbonate membrane (Corning, Life Sciences, NY). Briefly,
600 μl of the medium supplemented with 10% or 20% FCS was
added to the 24-well plate containing the transwell insert. For stimu-
lation of glioma migration, the lower side of the transwell insert was
precoated with 3 μg/ml of extracellular matrix (ECM) molecule vitro-
nectin (Invitrogen) by an overnight incubation at 4°C. Cells were col-
lected by trypsinization, resuspended in serum-free medium, plated at
1 × 104 cells/100 μl on top of the transwell membrane, and incubated
at 37°C for 4 or 24 hours. Medium was then aspirated, and the cells
that have migrated to the lower surface of the membrane were fixed
with 4% paraformaldehyde in phosphate-buffered saline. The top of
the membrane was then wiped and cleaned with a cotton swab, and
the membrane was stained with hematoxylin-eosin solution. The num-
ber of migrated cells to the lower surface of the membrane was counted
in four randomly selected fields of the slides under microscopic ob-
servation. Results were expressed as a percentage of migrating cells
relative to the total input of cells. These experiments were performed
three times in duplicate.
For the scratch assay, stable transfectants (1 × 105) were plated
onto 60-mm tissue culture dishes and allowed to create a confluent
monolayer. After aspirating themedium, the cell monolayer was scraped
in a straight line to make a “scratch” with a 1-ml pipette tip, and cell
debris were removed by washing the cells with phosphate-buffered
saline. The medium supplemented with 5% FCS was added, and clo-
sure of the scratch was photographed at 0, 24, 72, and 96 hours. The
number of migrating cells was determined by counting the cells that
migrated into the scratch area at the indicated time points. This experi-
ment was repeated three times in duplicate.
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Matrigel Invasion Assay In Vitro
Matrigel invasion assay was performed for the evaluation of inva-
sive capability in vitro by using transwell inserts containing an 8-μm
pore size polycarbonate membrane (Corning, Life Sciences, NY) coated
with 100 μl per well of Matrigel (Invitrogen). The puromycin-resistant
transfected cells (1 × 105 cells/100 μl of serum-free medium) were plated
on the top of the transwell membrane. The medium supplemented
with 10% FCS was added to the 24-well plate. After 72 hours of in-
cubation, cells that had migrated through the Matrigel and the lower
surface of the membrane were fixed, stained, and counted as descried
above. Results were expressed as a percentage of migrating cells relative
to the total input of cells. These experiments were performed three times
in duplicate.
Caspase-3 Activity
After puromycin selection for 14 days of LHX9-transfected and
mock-transfected glioma cells, caspase-3 activity was measured using a
colorimetric assay kit (CaspACE Assay System, Colorimetric; Promega)
according to the manufacturer’s instructions. As controls, SF188 and
KNS-42 cells were treated with 0.1 to 0.5 μM staurosporine (STS) or
with a combination of STS and 20 μM cell-permeable pan-caspase
inhibitor Z-VAD-FMK for 24 hours. Untreated glioma cells were used
as a negative control. Cell extracts were prepared by adding cell lysis
buffer at a concentration of 1 × 106 cells/ml, and the protein concentra-
tion of the cell lysates was determined using Bradford assay. Twenty-five
micrograms of the cell extracts and 2 μl of DEVD-pNA caspase sub-
strate labeled with chromophore p-nitroaneline (pNA), which is re-
leased from the substrate upon cleavage by DEVDase, were added
into 96-well plate and incubated for 4 hours at 37°C. The caspase-3
activity was determined by measuring the free pNA at 405 nm using
amicroplate reader (BioAnalyzer). This experimentwas performed three
times in duplicate.
Statistical Analysis
Data are presented as mean ± SD. Differences of the variables be-
tween groups were tested by Student’s t test or one-way analysis of vari-
ance test, and P ≤ .05 was considered statistically significant.
Results
Methylation Status of LHX9 in Pediatric HGG, PA, and
Glioma Cell Lines
To investigate the role of epigenetic alterations in pediatric malignant
gliomas on a genomewide scale and to identify novel genes silenced in
these tumors, we performed a DMH approach that enabled us to select
frequently methylated CGIs by comparing the hybridization pattern
of DNA amplicons derived from tumor samples and those derived
from normal tissues. We identified a novel frequently hypermethylated
CGIs in about five candidate genes. Among them, a CpG-rich DNA
fragment localized within the coding sequence of a LHX9 transcript
variant 2 encoding a LIM-hd transcription factor expressed in the de-
veloping brain [8,9] was found hypermethylated at the highest fre-
quency in five of nine high-grade gliomas compared with normal
brain tissue samples. Therefore, we focused on the LHX9 gene to further
verify the microarray data. First, we selected two CGI-associated regions:
LHX9 region 1 localized upstream of the transcriptional start site of
LHX9 (−1.642 to −1.303 bp) containing 22 CpG sites and LHX9 re-
gion 2 within the coding sequence (3 intron/4 exon) of LHX9 contain-
ing 33 CpG sites (Table 1A and Figure 1A). The 5′-LHX9 region 1,
which may possess promoter or enhancer activity, was identified by
Promoter 2.0 prediction [13] and CGI searcher programs as described
in the Materials and Methods section including the following criteria:
CG content greater than 50, Obs CpG/Exp CpG greater than 0.60,
and length of 100 bp or greater, whereas hypermethylation at LHX9
region 2 was found by the DMH approach. We next performed bisulfite
genomic sequencing to analyze the methylation levels of the 22 CpG
positions within LHX9 region 1 in a subset of nine pediatric high-grade
astrocytic tumors analyzed by DMH. Nontumorous pediatric brain
samples were used as controls. Analysis of bisulfite-modified DNA by
BiQ Analyzer Software [14] showed that the 339-bp upstream fragment
1 of LHX9 was unmethylated (≤2%) in normal pediatric brain tissues,
whereas extensive methylation of all CpG sites was observed in one
glioblastoma sample (Figure 1B) and a partial methylation of all CpG
sites was found in two tumor samples whereas one astrocytic tumor
showed evidence of methylation of a limited number of CpG sites
(5%). The remaining five glioma samples were unmethylated at all
CpG sites assessed. These findings demonstrated that four of the five
HGGs exhibiting hypermethylation at region 2 within LHX9 also
showed de novo methylation at region 1 by bisulfite sequencing.
Using a COBRA approach [19], we also wanted to quantitatively
estimate the aberrant DNAmethylation status of the two selected CpG-
rich regions of LHX9 gene in a larger set of 25 pediatric HGGs and
3 normal brain control samples, including those samples that have
been analyzed by DMH, and 4 pediatric glioma cell lines (CHLA-200,
SF188, KNS-42, and KG-1-C). De novo DNA methylation at the two
BstUI restriction sites of LHX9 region 1 was detected in 28% (7/25 cases;
Figure 1B) of the pediatric HGG samples and quantified to an average
of 20% methylated alleles compared with the three nonpathological
brain tissue samples that were unmethylated. Glioma cell lines SF188
and KNS-42 were completely methylated exhibiting an average of
98.5% methylated alleles, whereas CHLA-200 and KG-1-C cell lines
were unmethylated at the BstUI restriction sites of LHX9 fragment 1
(Figure 1B). To analyze the methylation status of the second LHX9 re-
gion, we used a nested PCR and a combination of two restriction endo-
nucleases, BstUI and TaqαI, and could therefore assess DNAmethylation
at 6 of 33 CpG sites. The COBRA approach of the two overlapping
PCR products of LHX9 region 2 revealed de novo methylation at all re-
striction sites in 88% (22/25 tumor samples) of pediatric HGGs and in
the four glioma cell lines and assessed to an average of 51% methylated
alleles and an average of 87% methylated alleles, respectively, in com-
parison to the unmethylated normal brain tissue samples (Figure 1C).
These results demonstrated a frequent hypermethylation of the second
CGI-associated region compared with the first upstream putative pro-
moter region of the LHX9 gene and with the normal brain tissue samples
that were unmethylated. Taken together, our data showed that the second
LHX9 fragment seems to be a critical target for DNA methylation in
pediatric HGGs.
To examine whether LHX9 gene is also hypermethylated in pediatric
low-grade gliomas, we analyzed the methylation profile of LHX9 in
14 pediatric PAs (WHO grade 1). The DNA methylation status of the
second CpG-rich LHX9 region, as it was more frequently methylated
in pediatric HGGs, was estimated by COBRA approach. De novo
methylation of a limited number of CpG positions at the LHX9 re-
gion 2 was detected in 29% (4/14 cases; Figure 1C) of tumor samples
and quantified to an average of 10% methylated alleles, indicating a
much lower level of methylation of LHX9 in pediatric PAs compared
with that of HGGs.
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Expression Analysis of LHX9 Gene in HGG, PA, and
Glioma Cell Lines
To determine the transcriptional expression levels of LHX9 in 11 pe-
diatric HGGs and 1 nontumorous pediatric brain sample for which
total RNA was available, we carried out cRT-PCR using specific RNA
competitor molecules for LHX9 and the housekeeping gene β-actin.
cDNA samples derived from normal testis were used as a positive con-
trol [20] for LHX9 gene expression (data not shown). The four glioma
cell lines were also analyzed. LHX9 expression was determined by a
titration of the constant amount of total RNA against serial dilutions
of exogenous competitor RNA and normalized to the transcript levels
of constitutively expressed β-actin. The cRT-PCR analysis showed that
the relative LHX9 mRNA levels were markedly reduced in 8 (73%) of
11 tumor samples (an average of 15-fold reduction) and in all glioma
cell lines (an average of 40-fold reduction) compared with the LHX9
mRNA level in normal brain tissue sample (Figure 2A). Three gliomas
displayed high LHX9 expression but lower than that of the normal
brain. To examine whether the CGI hypermethylation affects the
expression of LHX9, we next correlated methylation status with tran-
script levels of LHX9. From the 11 HGGs analyzed, 8 tumor samples
with extensive methylation at LHX9 region 1 or region 2 showed low
LHX9 mRNA expression, whereas 1 tumor sample with limited meth-
ylation and 2 cases without methylation at LHX9 displayed high ex-
pression levels. All four glioma cell lines with hypermethylated LHX9
pattern showed reduced LHX9 mRNA levels. These data indicated
a significant correlation (P < .0001) between hypermethylation and de-
creased or weak expression of LHX9 in HGGs and cell lines (Figure 2A,
scatter plot).
Analysis of the relative LHX9mRNA levels in the four only partially
methylated PAs revealed a four-fold lower LHX9 expression compared
with normal brain but approximately a four-fold higher transcriptional
level compared with that in extensively methylated HGGs (Figure 2A).
Together, these results demonstrated that the LHX9 gene was less
DNA-methylated in pediatric noninvasive pilocytic astrocytomas com-
pared with HGGs, indicating an inverse correlation between degree of
methylation and mRNA expression in gliomas.
Effect of Treatment of Glioma Cell Lines with a
Demethylating Agent
To estimate if the observed reduction of expression in HGGs is
associated with CGI hypermethylation of the LHX9 gene, the tran-
script levels and DNA methylation status of LHX9 were analyzed in
Figure 2. LHX9 mRNA expression in pediatric HGG, PA, and glioma cell lines. LHX9 expression levels were estimated by cRT-PCR in (A)
tumor samples and cell lines and (B) glioma cell lines before and after treatment with the demethylating agent 5-aza CdR. LHX9- specific
mRNA levels were quantified by titrating 250 ng of target RNA against serial dilutions of exogenous competitor RNA ranging from 0.8 to
150 pg and normalized to the transcript levels of constitutively expressed β-actin. (A) The cRT-PCR analysis showed that the relative
LHX9mRNA levels in HGG were markedly reduced in 8 (73%) of 11 tumor samples and in all 4 glioma cell lines compared with the LHX9
mRNA level in normal brain control sample (NB). LHX9 expression in PA was lower than in NB but not silenced as it is shown for the 8 of
11 HGGs and the glioma cell lines. Scatter plot represents a significant correlation (P< .0001) between hypermethylation and decreased
expression of LHX9 in HGG and glioma cell lines. (B) Comparison of the expression pattern of LHX9 treated with 5-aza CdR and untreated
glioma cell lines demonstrated that the transcription level in treated cells was significantly increased: ***P < .0001. Data represent the
means ± SD of three independent experiments.
706 LHX9 in Malignant Gliomas of Childhood Vladimirova et al. Neoplasia Vol. 11, No. 7, 2009
three glioma cell lines (CHLA-200, SF188, and KNS-42) before and
after treatment with the DNA methyltransferase inhibitor 5-aza CdR
(5 μM) for 4 days. The mRNA levels of LHX9 were assessed by cRT-
PCR (Figure 2B). The DNA methylation status of CpG-rich LHX9
region 2 in the cells before and after treatment with demethylating
agent was analyzed by COBRA (Figure 1C ). To verify the effect of
5-aza CdR treatment in our experiment, we examined the expres-
sion level of a PCDH-γ-A11 gene, which is known to be silenced
by methylation in glioma cells [16]. The RT-PCR analysis showed
that exposure of glioma cells to 5 μM 5-aza CdR induced reexpres-
sion of PCDH-γ-A11, confirming that demethylation using 5-aza
CdR was able to restore the expression from a promoter known to
be silenced by aberrant methylation in these cells (data not shown).
Comparison of the expression pattern of LHX9 in glioma cells incu-
bated with or without 5 μM 5-aza CdR demonstrated that the LHX9
transcription level in treated cells was increased to 12.5-fold (Fig-
ure 2B). In contrast, the relative mRNA level of LHX9 in treated
glioma cells was still lower than that in the normal brain tissue sam-
ple and assessed to an average of 30% expression. The COBRA assay
showed that the methylation of the BstUI restriction site at the CGI-
associated region 2 of LHX9 was reduced in cells after 5-aza CdR
treatment in comparison to untreated cells, indicating that the ex-
amined hypermethylation of the LHX9 fragment 2 was reversible
and may have contributed to reduced expression of LHX9.
Figure 3. Reexpression of LHX9 does not affect glioma cell growth. (A) Colony formation and (B) cell growth and proliferation assays
were performed after transfection with pCMV-XL4/LHX9 or empty vector (pCMV-XL6/mock) and puromycin selection for 14 days. (A)
Protein and mRNA overexpression of LHX9 in two pediatric glioma cell lines (SF188 and KNS-42) after transfection, and puromycin
selection was tested by Western blot analysis and RT-PCR. Western blot represents nuclear extracts of the stable transfectants probed
with antibody against Lhx9. LHX9 mRNA levels of puromycin-resistant transfected cells were assessed by RT-PCR. Equal loading was
confirmed by β-actin. Subsequently, stable transfectants were stained with 0.1% crystal violet in 20% methanol for colony formation
assay, and colonies with 50 cells or more were counted. (B) Growth of the puromycin-resistant LHX9-transfected or mock-transfected
glioma cells was assessed by counting the cells after 24, 48, and 72 hours of incubation at 37°C. Results were expressed as a mean
number of cells. Proliferation activity of the stable cell clones was also characterized by the MTT assay. The cell proliferation was de-
termined after 24, 48, and 72 hours of incubation at 37°C by measuring the converted formazan at 595 nm using a microplate reader.
LHX9 overexpression in stable transfectants was tested by RT-PCR analysis for each of the experiments performed. Data represent the
means ± SD of at least three independent experiments done in triplicate.
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Reexpression of LHX9 Does Not Affect Glioma Cell Growth
To assess the functional role of LHX9 in pediatric HGGs, we over-
expressed LHX9 in two pediatric glioma cell lines (SF188 and KNS-42).
After puromycin selection for 14 days, mRNA and protein overexpres-
sion of LHX9 was confirmed by RT-PCR and Western blot analyses
(Figure 3A), and stable clones were used for further experiments.
Glioma growth activity in puromycin-resistant transfectants was de-
termined by colony focus and proliferation assays. Colony focus assay
revealed similar numbers of colonies in both LHX9-transfected (SF188-
LHX9 and KNS-42-LHX9) and mock-transfected cells (Figure 3A).
Comparison of the proliferation activity of LHX9-transfected and mock
glioma cells using cell growth and MTT assays revealed no significant
differences at the three time points analyzed (P ≥ .05; Figure 3B). These
results demonstrated that the overexpression of LHX9 did not suppress
glioma cell growth suggesting that epigenetic modification of LHX9
expression does not affect glioma cell proliferation.
Figure 4. Reexpression of LHX9 inhibits glioma cell migration and invasion in vitro. Transwell migration, invasion (A), and scratch (B)
assays of the puromycin-resistant LHX9-transfected and mock-transfected glioma cell lines SF188 and KNS-42. (A) Transwell migra-
tion and invasion of LHX9-transfected glioma cells was significantly inhibited compared to mock-transfected cells both, in the presence
of 10% (***P = .0006 for SF188, *P = .01 for KNS-42) or 20% FCS (***P = .0008 for SF188, ***P = .0003 for KNS-42) in the medium
after 24 hours of incubation. Coating the lower side of the transwell insert with ECM molecule vitronectin (**P = .005 for SF188, *P =
.01 for KNS-42) or with Matrigel (**P = 0084 for SF188, *P = .01 for KNS-42) significantly stimulated the migration or invasion of mock-
transfected cells after 72 hours of incubation compared with LHX9-transfected cells. LHX9 overexpression in stable transfectants was
confirmed by RT-PCR analysis for each of the experiments performed. (B) Confluent monolayers of KNS-42-LHX9–transfected and
KNS-42 mock-transfected glioma cells were scratched, and the complete closure of the scratch was achieved after 96 hours and photo-
graphed. Note that the mock-transfected glioma cells migrated and covered the scratch, whereas a significant area of the scratch remains
uncovered in LHX9-transfected cells. Similar results were observed for the SF188-transfected cell clones (see the graph). The number of
migrating cells was determined by counting the cells that migrated into the scratch area at the indicated time points (***P < .0001). Data
represent the means ± SD of three independent experiments done in duplicates.
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LHX9 Overexpression Inhibits Glioma Cell Migration and
Invasion But Does Not Induce Apoptosis
To investigate whether LHX9 expression is involved in glioma cell
migration, we performed transwell migration and scratch assays in vitro.
Transwell migration assay represented an in vitro model for invasive
migration. As shown in Figure 4A, reexpression of LHX9 significantly
decreased the migratory potential of the stable LHX9-transfected cell
clones through the transwell membrane compared with the mock-
transfected cells. Coating the lower side of the transwell insert with
the ECM molecule vitronectin significantly stimulated the migration
of glioma cells. However, the mock-transfected cells again showed a
higher migratory activity compared with the LHX9-transfected cells
(Figure 4A). A similar result was observed during evaluation of the
migratory ability of the glioma cells using a scratch assay in vitro. As
shown in Figure 4B, KNS-42-mock and SF188-mock cells migrated
and completely closed the scratch after 96 and 72 hours, respectively,
whereas the significant area of the scratch remained uncovered in KNS-
42-LHX9 and SF188-LHX9 cells. Together, these findings showed that
LHX9 expression may impact the migration of pediatric glioma cells.
To further support the role of LHX9 in the invasive behavior of
glioma cells, we performed an invasion assay using Matrigel, a base-
ment membrane matrix containing laminin, collagen IV, entactin, and
heparin sulfate proteoglycan. Again, an exogenous expression of LHX9
in the stable transfectants resulted in a significant reduction of inva-
sion through Matrigel compared with the mock-transfected cells (Fig-
ure 4A) indicating that LHX9 plays a specific role in pediatric glioma
cell invasion.
On the basis of the previous data showing a direct correlation be-
tween invasion and apoptosis resistance in malignant gliomas [21], we
measured caspase-3 activity of puromycin-resistant LHX9-transfected
and mock cells to determine whether the exogenous LHX9 expression
in these cells may directly induce apoptosis. We were not able to detect
a significant number of cells that were undergoing apoptosis (Figure 5)
indicating that LHX9 expression is not directly involved in the induc-
tion of apoptosis in pediatric glioma cells.
Discussion
In the current study, we provide evidence that LHX9 (human
LIM-hd 9 transcription factor) is not only frequently hypermethylated
in pediatric malignant astrocytomas but that this epigenetic alteration
of the LHX9 gene is associated with reduced mRNA expression and is
involved in the migratory and invasive phenotype of glioma cells in a
tumor-specific manner.
LHX9 belongs to a family of LIM-hd transcription factors containing
a DNA-binding domain and two highly conserved cystein-rich zinc-
binding domains involved in protein-protein interactions [22,23]. The
roles of the LIM-hd–encoding genes have been mostly defined in the
context of nervous system development where they are critically involved
in cell determination [24]. Although it is known that LHX9 is strongly
expressed in embryonic mouse brain, its expression in brain tumors
has not yet been a matter of investigation. Using DMH, bisulfite se-
quencing, and COBRA assays, we examined for the first time the
DNAmethylation status and the expression profile of LHX9 in pediatric
astrocytic tumors. Other LIM-hd factors have been shown to exhibit
an epigenetic transcriptional regulation and have been implicated in
tumorigenesis. For instance, the LHX6 gene has been found to be a sen-
sitive DNA methylation biomarker in head and neck carcinomas [25].
Recent data using gene expression profiling have identified an increased
expression of LHX2 in PAs and ependymomas as well as in normal
murine astrocytes and neural stem cells [26]. As far as we are aware,
LHX9 hypermethylation and expression have not been previously in-
vestigated in astrocytomas or other tumor types.
Because down-regulation of gene expression through promoter
hypermethylation has been reported to be an important mechanism
of transcriptional silencing inmany tumors [27], we focused to examine
1) the DNA methylation status of two LHX9 CpG-rich regions and 2)
the possible functional implication of methylation on LHX9 expression
in pediatric high-grade astrocytomas. We established a COBRA assay
using the restriction endonuclease BstUI or a combination of the two
restriction endonucleases BstUI and TaqαI to analyze the methylation
status of the two CGI-associated LHX9 regions in 39 pediatric tumor
Figure 5. Reexpression of LHX9 does not induce apoptosis. Apoptosis in LHX9-transfected and mock-transfected glioma cells was as-
sessed by measuring the caspase-3 activity after 14 days of selection with puromycin. LHX9 overexpression was confirmed by Western
blot analysis. Cells lysates treated with STS were used as a positively induced apoptosis control, whereas cells lysates treated with a
combination of STS and cell-permeable pan-caspase inhibitor Z-VAD-FMK (Z-VAD-FMK + STS) were set up as an inhibited apoptosis con-
trol. Untreated glioma cells were used as a negative control ((−) control). The caspase-3 activity was determined by measuring the free
pNA at 405 nm using a microplate reader (see Materials and Methods). Both the LHX9-transfected (SF188-LHX9 and KNS-42-LHX9) and the
mock-transfected (SF188-mock and KNS-42-mock) cells did not induce apoptosis. Data represent the means ± SD of three independent
experiments done in duplicate.
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cases, 3 normal brain control samples, and 4 pediatric glioma cell lines.
Our results demonstrated that the second CGI-associated region within
LHX9 seems to be a critical target for DNA methylation because it was
more frequently hypermethylated in most of the HGGs and glioma cell
lines. Moreover, our data suggest a potential association between hyper-
methylation at CpG-rich region 2 and reduced mRNA expression of
the LHX9 transcript variant 2 in pediatric malignant astrocytic tumors
and glioma cell lines as we found that glioma samples exhibiting hyper-
methylation at this LHX9 fragment expressed decreased transcript levels
relative to unmethylated normal brain tissue and that treatment of
glioma cells with the demethylating reagent (5-aza CdR) restored LHX9
mRNA expression. The undigested LHX9 band observed in some of
the samples treated with the restriction endonucleases may represent
unmethylated alleles in the tumors and thus may reflect a cellular
heterogeneity of high-grade astrocytomas. Because PAs are low-grade
nondiffuse gliomas that lack the typical molecular alterations associ-
ated with diffuse high-grade astrocytomas [28,29] and expressed a
large number of genes involved in brain development [30,31], we also
analyzed the methylation profile of LHX9 in these tumors and found
that the CpG-rich fragment within the coding sequence of LHX9
gene was methylated to a limited extend. These results clearly demon-
strated that hypermethylation of LHX9 represents a frequent and
tumor-specific event in pediatric malignant astrocytomas and may
contribute to their tumor biology. Furthermore, hypermethylation
of the CpG-rich LHX9 regions was not a feature of normal pediatric
brain tissues as we showed by bisulfite sequencing and COBRA, and
it likely represents a tumor-associated event that occurs de novo in the
development of pediatric astrocytic tumors.
Exogenous expression of LHX9 in pediatric glioma cell lines ex-
hibiting extensive methylation of the CGI-associated LHX9 regions
did not affect glioma cell growth and apoptosis but significantly de-
creased cell motility and invasive behavior in vitro indicating that this
gene is specifically involved in glioma cell migration and invasion. A
number of genes known to be involved in cell motility and adhesion
are deregulated in invasive and metastatic cancer cells, and altera-
tion of the expression patters of these genes can promote or suppress
cancer cell invasiveness and metastasis [32]. As invasive behavior is
a hallmark of HGGs, our results suggest that the epigenetic modifi-
cation of LHX9 expression promotes glioma cell motility, whereas re-
expression of this gene in extensively methylated cells suppressed cell
migration and invasion indicating that LHX9 silencing may contribute
to the migratory and invasive phenotype of glioma cells.
On the basis of the previous data that showed high degree of ho-
mology between the LIM domains of Lhx9 and those of Lhx2 and co-
expression of these two genes in numerous regions of the developing
brain [8] and that increased expression of LHX2 was detected in PAs
[26], we suggested that LHX9 may also be expressed by these benign,
nondiffuse gliomas. Our results showed a lack of silencing by DNA
methylation of the LHX9 gene in PAs. This may be directly related
to the noninvasive behavior of these tumors. Further work such as iden-
tification of transcriptional targets of LHX9 has to elucidate the specific
role of LHX9 in pediatric tumor progression and brain invasion.
In summary, we have identified frequent hypermethylation of a
CGI-associated region of the LHX9 gene in pediatric malignant astro-
cytomas associated with reduced LHX9 gene expression. Reexpression
of LHX9 suppressed glioma migration and invasion without directly
affecting proliferation or apoptosis, suggesting that the frequent epige-
netic silencing of the LHX9 gene is implicated in the invasive behavior
of pediatric HGGs. Further studies of the mechanism(s) by which
LHX9 mediates glioma cell migration and invasiveness will contribute
to a better understanding of its role in glioma biology.
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